A Phase 3 interventional study of Mirikizumab in Psoriasis, sponsored by Eli Lilly and Company. Terminated at 229 sites in 19 countries. Open to participants aged 18 Years and older. Per ClinicalTrials.gov, last updated 2023-03-21.
Sponsored by Eli Lilly and Company · Phase 3, Interventional, and Treatment
Help build ClinicalTrials.gg — short surveys, remote interviews or testing, in your language. Take part →
Among 36 studies in Psoriasis by Eli Lilly and Company — 1 open to participants now, 1 under way, none of them phase 3. Psoriasis · Eli Lilly and Company.
Among the 36 studies in Psoriasis by Eli Lilly and Company, this one has the largest enrollment, is one of 6 that started in 2018, is one of 15 in phase 3, and was the 24th registered.
2,030 studies on the registry are indexed under Psoriasis; 276 are open to participants now.
Browse Psoriasis studies →1 of the 36 studies in Psoriasis by Eli Lilly and Company is open now, in 1 country. Recruiting first, the newest first:
Eli Lilly and Company · Sites in United States
Ages 18+
By country, each count listing its studies:
Of the 173 Psoriasis studies recruiting now, 91 (53%) set no upper age limit and 66 (38%) stop at 75 or younger; 25 take children under 18; 40 take healthy volunteers.
This study: 18 Years and older · all sexes · no healthy volunteers.
The full table on the hub →This tab as a report to print or save as PDF → With an account.
36 studies; the count open now beside each. This study's row is marked.
First in 2009; this study’s year is marked. 6 started in 2018.
By drug class, each counting the studies that test any of its medicines:
This study's enrollment of 1,936 is above the median of 75 across 1,567 interventional studies indexed under Psoriasis.
Median enrollment 181 across the 36 interventional studies. Of the 35 that completed or were terminated, 28 (80%) have results posted.
This tab as a report to print or save as PDF → With an account.
Eli Lilly and Company is the lead sponsor of 2,108 studies on the registry; 153 are open to participants now.
Of its 537 completed or terminated interventional studies of FDA-regulated products, 358 (67%) have results posted.
None of the studies under way reaches primary completion within a year.
Among the 36 studies in Psoriasis by Eli Lilly and Company, from their registry updates:
Nothing recorded among them since 2026-09-25.
This tab as a report to print or save as PDF → With an account.
The purpose of this study is to evaluate the long-term safety and maintenance of efficacy of mirikizumab in participants with moderate-to-severe plaque psoriasis.
Go through the criteria one by one — yes, no or not sure — and take the list to your doctor or the study team. Kept in this browser only.
Exclusion Criteria:
Underlined terms in the criteria open these too. Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Contraception
Ways of preventing pregnancy. “Highly effective” methods fail less than 1% of the time a year when used correctly — for example an IUD or an implant.
Criteria usually say which methods count and how long to keep using them after the last dose, sometimes for male participants too. Some studies accept a partner’s vasectomy if it was confirmed successful and that person is the participant’s only sexual partner.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Childbearing potential
Able to become pregnant: from the first period until menopause, unless permanently unable to through surgery (removal of the womb, or of both ovaries or both fallopian tubes).
Criteria for people of childbearing potential usually ask for a negative pregnancy test and for contraception during the study and for a time after it.
Explained by clinicaltrials.gg, not part of the registry record. The study team decides who can take part.
Participants received 125 mg mirikizumab administered subcutaneously (SC) every eight weeks (Q8W).
Drug: Mirikizumab
Participants received 250 mg mirikizumab administered SC Q8W excluding participants who received secukinumab of their originating study (AMAJ)
Drug: Mirikizumab
Participants from previous originating study \[who received secukinumab (AMAJ)\] received 250 mg mirikizumab administered SC Q8W.
Drug: Mirikizumab
Administered SC
Also known as: LY3074828
Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1
The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.
Time frame: Week 104
Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Time frame: Week 104
Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100)
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
Time frame: Week 104
Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline
PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.
Time frame: Week 104
Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5
The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.
Time frame: Week 104
Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline
The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.
Time frame: Baseline, Week 104
Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).
Time frame: Baseline, Week 104
Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).
Time frame: Baseline, Week 104
| Milestone | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Started | 527 | 1020 | 389 |
| Received at least one dose of study drug | 527 | 1020 | 389 |
| From amaf | 35 | 132 | 0 |
| From amak | 83 | 390 | 0 |
| From amaj | 409 | 498 | 389 |
| Completed | 0 | 0 | 0 |
| Not completed | 527 | 1020 | 389 |
| Withdrew: Adverse event | 18 | 14 | 9 |
| Withdrew: Death | 2 | 6 | 0 |
| Withdrew: Lack of efficacy | 5 | 12 | 18 |
| Withdrew: Lost to follow-up | 9 | 20 | 2 |
| Withdrew: Pregnancy | 2 | 4 | 3 |
| Withdrew: Study terminated by sponsor | 469 | 907 | 331 |
| Withdrew: Withdrawal by subject | 22 | 47 | 22 |
| Withdrew: Due to exclusion criteria of amaj study | 0 | 0 | 1 |
| Withdrew: Physician decision | 0 | 8 | 2 |
| Withdrew: Protocol violation | 0 | 1 | 1 |
| Withdrew: Sponsor decision | 0 | 1 | 0 |
| Milestone | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Started | 453 | 861 | 333 |
| Completed | 0 | 0 | 0 |
| Not completed | 453 | 861 | 333 |
| Withdrew: Adverse event | 11 | 11 | 8 |
| Withdrew: Death | 1 | 0 | 0 |
| Withdrew: Lack of efficacy | 4 | 9 | 13 |
| Withdrew: Lost to follow-up | 4 | 14 | 3 |
| Withdrew: Pregnancy | 1 | 4 | 1 |
| Withdrew: Study terminated by sponsor | 396 | 750 | 273 |
| Withdrew: Withdrawal by subject | 36 | 65 | 31 |
| Withdrew: Physician decision | 0 | 3 | 1 |
| Withdrew: Site terminated by sponsor | 0 | 1 | 0 |
| Withdrew: Study discontinued by sponsor | 0 | 2 | 1 |
| Withdrew: Second follow-up visit: patient refused | 0 | 1 | 0 |
| Withdrew: Study terminated & subject missed follow-up visit | 0 | 1 | 0 |
| Withdrew: To meet exclusion criteria of the amaj study | 0 | 0 | 1 |
| Withdrew: Second follow-up not done, unable to reach patient | 0 | 0 | 1 |
The sPGA is the physician's determination of the participant's psoriasis (PsO) lesions overall at a given time point. Lesions were categorized by descriptions for induration, erythema, and scaling. Participant's PsO was assessed as 0 (clear), 1 (minimal), 2 (mild), 3 (moderate), 4 (severe), or 5 (very severe). An sPGA responder was defined as having a post-baseline sPGA score of "0" or "1" with at least a 2-point improvement from baseline. Participants who did not meet the clinical response criteria or had missing data at Week 104 were considered non-responders for non-responder Imputation (NRI) analysis.
| percentage of participants | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Percentage of Participants With a Static Physician's Global Assessment Among Those Who Entered the Study With a sPGA of 0,1 | 46.7 (42.2 to 51.2) | 55.7 (52.3 to 59.1) | 38.9 (33.3 to 44.4) |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
| percentage of participants | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Percentage of Participants Who Maintained a ≥90% Improvements in Psoriasis Area and Severity Index (PASI) 90 Among Those Who Entered the Study With a PASI 90 | 49.3 (44.8 to 53.9) | 56.8 (53.4 to 60.2) | 39.4 (33.9 to 44.9) |
PASI combines the extent of body surface involvement in 4 anatomical regions (head, trunk, arms, and legs) and the severity of scaling, redness, and plaque induration/infiltration (thickness) in each region. For each region the percent area of skin involved was estimated from 0 (0%) to 6 (90%-100%) and severity was estimated by clinical signs of erythema, induration and scaling with a scores range from 0 (no involvement) to 4 (severe involvement). Each area is scored separately and the scores then combined for the final PASI. Final PASI calculated as: sum of severity parameters for each region \* area score \* weighing factor \[head (0.1), upper limbs (0.2), trunk (0.3), lower limbs (0.4)\]. Overall scores range from 0 (no PsO) to 72 (the most severe disease).
| percentage of participants | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Percentage of Participants Achieving a 100% Improvement in Psoriasis Area and Severity Index (PASI 100) | 30.4 (26.4 to 34.3) | 36.4 (33.4 to 39.3) | 22.6 (18.5 to 26.8) |
PSS is a patient-administered assessment of 4 symptoms (itch, pain, stinging, and burning); 3 signs (redness, scaling, and cracking); and 1 item on the discomfort related to symptoms/signs. The overall severity for each individual symptom/sign from the patient's psoriasis is indicated by selecting the number from a numeric rating scale (NRS) of 0 to 10 that best describes the worst level of each symptom/sign in the past 24 hours, where 0=no symptom/sign and 10=worst imaginable symptom/sign. In addition, a symptoms score ranging from 0 (no symptoms) to 40 (worst imaginable symptoms), and a sign score of 0 (no signs) to 30 (worst imaginable signs) will be reported.
| percentage of participants | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Percentage of Participants With a Psoriasis Symptoms Scale (PSS) Symptom Score of 0 (Free of Itch, Pain, Stinging, and Burning) in Those With a PSS Symptoms Score ≥1 at Baseline | 31.1 (27.1 to 35.1) | 33.6 (30.7 to 36.5) | 23.4 (19.1 to 27.7) |
The DLQI is a patient-reported, 10-question, quality-of-life questionnaire that covers 6 domains including symptoms and feelings, daily activities, leisure, work and school, personal relationships, and treatment. Response categories include "Not at all," "A little," "A lot," and "Very much," with corresponding scores of 0, 1, 2, and 3 respectively. Questions 3-10 also have an additional response category of "Not relevant" which is scored as "0". Totals range from 0 to 30 (less to more impairment). A DLQI total score of 0 to 1 is considered as having no effect on a patient's health-related quality of life (HRQoL), and a 5-point change from baseline is considered as the minimal clinically important difference (MCID) threshold.
| percentage of participants | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Percentage of Participants Achieving a Dermatology Life Quality Index (DLQI) Total Score of (0,1) With at Least a 5-Point Improvement (Reduction) From Baseline in Participants With a Baseline DLQI Total Score ≥5 | 41.5 (37.1 to 45.9) | 47.3 (44.1 to 50.5) | 34.5 (29.5 to 39.5) |
The PPASI is a composite score derived from the sum scores for erythema, induration, and desquamation multiplied by a score for the extent of palm and sole area involvement, ranging from 0 (no PPASI) to 72 (most severe PPASI). The PPASI was only assessed if participants have palmoplantar psoriasis at baseline.
| score on a scale | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Change in Palmoplantar Psoriasis Severity Index (PPASI) Total Score in Participants With Palmoplantar Involvement at Baseline | -6.55 ± 7.058 | -6.80 ± 8.391 | -7.38 ± 6.632 |
The PSSI is a physician assessment of erythema, induration and desquamation and percent of scalp that is covered with a scores range from 0 (none) to 4 (very severe). The composite score is derived from the sum of scores for erythema, induration, and desquamation multiplied by the score recorded for the extent of the scalp area involved, 1 (\<10%) to 6 (90%-100%) with a total score ranging from 0 (less severity) to 72 (more severity).
| score on a scale | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Change in Psoriasis Scalp Severity Index (PSSI) Total Score in Participants With Scalp Involvement at Baseline | -20.9 ± 15.79 | -19.5 ± 13.48 | -19.6 ± 13.44 |
The NAPSI scale is used to evaluate the severity of fingernail bed Ps and fingernail matrix PsO by area of involvement. The fingernail is divided into quadrants. Each fingernail is given a score for fingernail bed PsO 0 (none) to 4 (PsO in 4 quadrants of the fingernail) and fingernail matrix PsO 0 (none) to 4 (Ps in 4 quadrants of the matrix), depending on the presence (score of 1) or absence (score of 0) of any of the features of fingernail bed or matrix PsO in each quadrant. The sum of all fingernails equals the total NAPSI score range is from 0 (no effect) to 80 (more severe psoriasis).
| score on a scale | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W |
|---|---|---|---|
| Change in Nail Psoriasis Severity Index (NAPSI) Total Score in Participants With Fingernail Involvement at Baseline | -19.4 ± 17.75 | -21.0 ± 17.69 | -22.2 ± 18.75 |
Collected over Treatment Period: Baseline Up To 160 Weeks, Follow-up Period: 0-12 Weeks. Non-serious events are listed at a 0% frequency threshold.
| Group | Deaths | Serious | Other |
|---|---|---|---|
| 125 Milligram (mg) Mirikizumab Q8W | 2/527 (0.4%) | 55/527 (10.4%) | 388/527 (73.6%) |
| 250 mg Mirikizumab Q8W Excluding Secukinumab | 6/1,020 (0.6%) | 88/1,020 (8.6%) | 756/1,020 (74.1%) |
| Secukinumab/250 mg Mirikizumab Q8W | 0/389 (0%) | 35/389 (9%) | 288/389 (74%) |
| 125 Milligram (mg) Mirikizumab Q8W Follow-up Period | 1/453 (0.2%) | 7/453 (1.5%) | 70/453 (15.5%) |
| 250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up Period | 0/861 (0%) | 6/861 (0.7%) | 120/861 (13.9%) |
| Secukinumab/250 mg Mirikizumab Q8W Follow-up Period | 0/333 (0%) | 0/333 (0%) | 47/333 (14.1%) |
| Event | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | 125 Milligram (mg) Mirikizumab Q8W Follow-up Period | 250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up Period | Secukinumab/250 mg Mirikizumab Q8W Follow-up Period |
|---|---|---|---|---|---|---|
| Covid-19 pneumoniaInfections and infestations | 5/527 | 8/1020 | 2/389 | 0/453 | 0/861 | 0/333 |
| Neovaginal complicationInjury, poisoning and procedural complications | 0/159 | 0/309 | 1/110 | 0/130 | 0/259 | 0/89 |
| EndometriosisReproductive system and breast disorders | 0/159 | 0/309 | 1/110 | 0/453 | 0/861 | 0/333 |
| Haemorrhagic ovarian cystReproductive system and breast disorders | 0/159 | 0/309 | 1/110 | 0/130 | 0/259 | 0/89 |
| Uterine polypReproductive system and breast disorders | 0/159 | 0/309 | 1/110 | 0/130 | 0/259 | 0/89 |
| Acute myocardial infarctionCardiac disorders | 2/527 | 2/1020 | 3/389 | 0/453 | 0/861 | 0/333 |
| CellulitisInfections and infestations | 0/527 | 1/1020 | 2/389 | 0/453 | 0/861 | 0/333 |
| Atrial fibrillationCardiac disorders | 0/527 | 4/1020 | 1/389 | 0/453 | 0/861 | 0/333 |
| Pancreatitis acuteGastrointestinal disorders | 2/527 | 1/1020 | 0/389 | 0/453 | 0/861 | 0/333 |
| PneumoniaInfections and infestations | 2/527 | 2/1020 | 1/389 | 0/453 | 0/861 | 0/333 |
| Event | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | 125 Milligram (mg) Mirikizumab Q8W Follow-up Period | 250 mg Mirikizumab Q8W Excluding Secukinumab Follow-up Period | Secukinumab/250 mg Mirikizumab Q8W Follow-up Period |
|---|---|---|---|---|---|---|
| NasopharyngitisInfections and infestations | 55/527 | 157/1020 | 43/389 | 5/453 | 11/861 | 5/333 |
| ArthralgiaMusculoskeletal and connective tissue disorders | 30/527 | 87/1020 | 19/389 | 0/453 | 1/861 | 2/333 |
| Upper respiratory tract infectionInfections and infestations | 22/527 | 54/1020 | 29/389 | 5/453 | 5/861 | 4/333 |
| Covid-19Infections and infestations | 33/527 | 66/1020 | 26/389 | 16/453 | 11/861 | 6/333 |
| HeadacheNervous system disorders | 18/527 | 55/1020 | 21/389 | 2/453 | 7/861 | 2/333 |
| Back painMusculoskeletal and connective tissue disorders | 25/527 | 48/1020 | 20/389 | 0/453 | 4/861 | 0/333 |
| HypertensionVascular disorders | 22/527 | 52/1020 | 14/389 | 0/453 | 3/861 | 0/333 |
| Injection site reactionGeneral disorders | 6/527 | 19/1020 | 19/389 | 1/453 | 1/861 | 0/333 |
| CoughRespiratory, thoracic and mediastinal disorders | 16/527 | 28/1020 | 8/389 | 1/453 | 2/861 | 0/333 |
| Urinary tract infectionInfections and infestations | 11/527 | 30/1020 | 9/389 | 0/453 | 5/861 | 1/333 |
All randomized participants.
| Age, Continuous(years) | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | Total |
|---|---|---|---|---|
| Mean | 47.90 ± 13.81 | 47.00 ± 12.87 | 46.50 ± 14.41 | 47.10 ± 13.45 |
| Sex: Female, Male(Participants) | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | Total |
|---|---|---|---|---|
| Female | 159 | 309 | 110 | 578 |
| Male | 368 | 711 | 279 | 1358 |
| Ethnicity (NIH/OMB)(Participants) | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | Total |
|---|---|---|---|---|
| Hispanic or Latino | 29 | 63 | 20 | 112 |
| Not Hispanic or Latino | 79 | 150 | 53 | 282 |
| Unknown or Not Reported | 419 | 807 | 316 | 1542 |
| Race (NIH/OMB)(Participants) | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | Total |
|---|---|---|---|---|
| American Indian or Alaska Native | 15 | 48 | 2 | 65 |
| Asian | 89 | 217 | 63 | 369 |
| Native Hawaiian or Other Pacific Islander | 1 | 1 | 1 | 3 |
| Black or African American | 5 | 18 | 6 | 29 |
| White | 415 | 734 | 315 | 1464 |
| More than one race | 2 | 2 | 2 | 6 |
| Unknown or Not Reported | 0 | 0 | 0 | 0 |
| Region of Enrollment(Participants) | 125 Milligram (mg) Mirikizumab Q8W | 250 mg Mirikizumab Q8W Excluding Secukinumab | Secukinumab/250 mg Mirikizumab Q8W | Total |
|---|---|---|---|---|
| Argentina | 32 | 30 | 23 | 85 |
| Australia | 16 | 21 | 19 | 56 |
| Canada | 26 | 44 | 24 | 94 |
| Czechia | 25 | 35 | 28 | 88 |
| France | 20 | 15 | 18 | 53 |
| Germany | 65 | 136 | 42 | 243 |
| Hungary | 23 | 27 | 20 | 70 |
| Israel | 12 | 15 | 15 | 42 |
| Italy | 7 | 5 | 5 | 17 |
| Japan | 39 | 86 | 37 | 162 |
| Mexico | 15 | 56 | 0 | 71 |
| Poland | 75 | 157 | 47 | 279 |
| Russia | 3 | 43 | 0 | 46 |
| South Korea | 24 | 68 | 13 | 105 |
| Spain | 24 | 22 | 24 | 70 |
| Taiwan | 9 | 44 | 0 | 53 |
| United Kingdom | 2 | 2 | 1 | 5 |
| United States | 110 | 214 | 73 | 397 |
Showing the first 100 of 229 sites across 19 countries. Choose a country and city above to see the rest.
PDFs hosted by the registry, ClinicalTrials.gov.
Plan to share: Yes — Lilly provides access to the individual patient data from studies on approved medicines and indications as defined by the sponsor specific information on ClinicalStudyDataRequest.com. This access is provided in a timely fashion after the primary publication is accepted. Researchers need to have an approved research proposal submitted through ClinicalStudyDataRequest.com. Access to the data will be provided in a secure data sharing environment after signing a data sharing agreement.
Ran from Sep 2018 to primary completion in Feb 2022, 41 months.
Results were first posted in Mar 2023, 1 year 1 month after primary completion.
How these figures are worked out, and which studies are left out of them.
This study is terminated, as verified in Mar 2023. You cannot join it, but the record below documents what was studied.
Get an email when the registry record changes — status, dates, results — or when someone posts here.
Sign in to followQuestions and observations about this study, from anyone following it. Not medical advice, and not a channel to the study team — their contact details are on the registry record.
Sign in to join the discussion. Reading takes no account; posting does. You choose a display name, and a pseudonym is the default.
Nothing here yet. If you are running this trial, taking part in it, or weighing whether to, this is the place to say so.
Studies of the drug tested here: Mirikizumab